Company news

Vor Biopharma Inc. news in 2025

Vor Biopharma Inc.'s news releases, calls and decks from 2025, newest first.

View company

Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors

December 23, 2025

Vor Bio Announces $150 Million Private Placement

December 15, 2025

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 13, 2025

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

November 10, 2025

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

November 10, 2025

Vor Bio to Participate in Upcoming Investor Conferences

November 7, 2025

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

November 3, 2025

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 31, 2025

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

October 29, 2025

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease

October 22, 2025

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025

October 17, 2025

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

October 16, 2025

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025

September 29, 2025

Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer

September 23, 2025

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

September 17, 2025

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

September 12, 2025

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

September 2, 2025

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

August 27, 2025

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

August 13, 2025

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

August 4, 2025

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

July 21, 2025

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

July 17, 2025

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

July 10, 2025

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025

Vor Bio Announces $175 Million Private Placement

June 25, 2025

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

June 25, 2025

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

May 8, 2025

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

March 20, 2025

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

February 12, 2025

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

February 2, 2025

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

January 7, 2025

Decks in 2025